Literature DB >> 7852317

Cell-mediated catabolism of aggrecan. Evidence that cleavage at the "aggrecanase" site (Glu373-Ala374) is a primary event in proteolysis of the interglobular domain.

M W Lark1, J T Gordy, J R Weidner, J Ayala, J H Kimura, H R Williams, R A Mumford, C R Flannery, S S Carlson, M Iwata.   

Abstract

A rat chondrosarcoma cell line and primary bovine chondrocytes have been used to study cell-mediated aggrecan catabolism. Addition of 1 microM retinoic acid to chondrosarcoma cultures resulted in aggrecan proteolysis with the release of greater than 90% of the cell layer aggrecan into the medium within 4 days. NH2-terminal sequencing of chondroitin sulfate-substituted catabolic products gave a single major NH2-terminal sequence of ARGNVILTXK, initiating at Ala374. This showed that the proteinase, commonly referred to as "aggrecanase," which cleaves the Glu373-Ala374 bond of the interglobular domain of aggrecan (Sandy, J. D., Neame, P. J., Boynton, R. E., and Flannery, C. R. (1990) J. Biol. Chem. 266, 8683-8685), is active in this cell system. Aggrecan G1 domain, generated by cleavage of the interglobular domain, was also liberated during catabolism and this was characterized with three antipeptide antisera. Anti-CDAGWL was used as a general probe for G1 domain. Anti-FVDIPEN was used to specifically detect G1 domain with COOH terminus of Asn341, the form which is readily generated by cleavage of aggrecan by a wide range of matrix metalloproteinases. Anti-NITEGE antiserum was used to specifically detect G1 domain with COOH terminus of Gln373, the form which is the expected product of "aggrecanase"-mediated cleavage of aggrecan. Western blot analysis indicated that a single form of G1 domain of about 60 kDa was formed. G1 domain of this size reacted with both anti-CDAGWL and anti-NITEGE but not with anti-FVDIPEN. Similar experiments with primary bovine chondrocyte cultures, treated with either retinoic acid or interleukin 1, showed that two forms of catabolic G1 domain, of about 62 and 66 kDa, were formed. Both of these forms reacted on Western blots with anti-CDAGWL and also with anti-NITEGE. It is suggested that cell-mediated catabolism of the aggrecan interglobular domain in these culture systems, whether promoted by retinoic acid or interleukin 1, primarily involves cleavage of the Glu373-Ala374 bond by aggrecanase. The accumulation of G1 domain with a COOH-terminal of Glu373 shows that such aggrecanase-mediated cleavage can occur independent of the cleavage of the Asn341-Phe342 bond by matrix metalloproteinases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7852317     DOI: 10.1074/jbc.270.6.2550

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Catabolism of aggrecan, decorin and biglycan in tendon.

Authors:  S G Rees; C R Flannery; C B Little; C E Hughes; B Caterson; C M Dent
Journal:  Biochem J       Date:  2000-08-15       Impact factor: 3.857

2.  Intact aggrecan and fragments generated by both aggrecanse and metalloproteinase-like activities are present in the developing and adult rat spinal cord and their relative abundance is altered by injury.

Authors:  M L Lemons; J D Sandy; D K Anderson; D R Howland
Journal:  J Neurosci       Date:  2001-07-01       Impact factor: 6.167

Review 3.  Articular cartilage chondrons: form, function and failure.

Authors:  C A Poole
Journal:  J Anat       Date:  1997-07       Impact factor: 2.610

4.  Change in the synthesis rates of ocular retinoic acid and scleral glycosaminoglycan during experimentally altered eye growth in marmosets.

Authors:  David Troilo; Debora L Nickla; James R Mertz; Jody A Summers Rada
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

5.  Mature bovine articular cartilage contains abundant aggrecan that is C-terminally truncated at Ala719-Ala720, a site which is readily cleaved by m-calpain.

Authors:  Hidefumi Oshita; John D Sandy; Kiichi Suzuki; Atsushi Akaike; Yun Bai; Tomohiro Sasaki; Katsuji Shimizu
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

Review 6.  Lectican proteoglycans, their cleaving metalloproteinases, and plasticity in the central nervous system extracellular microenvironment.

Authors:  M D Howell; P E Gottschall
Journal:  Neuroscience       Date:  2012-05-22       Impact factor: 3.590

7.  Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.

Authors:  M W Lark; E K Bayne; J Flanagan; C F Harper; L A Hoerrner; N I Hutchinson; I I Singer; S A Donatelli; J R Weidner; H R Williams; R A Mumford; L S Lohmander
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

8.  The intermediates of aggrecanase-dependent cleavage of aggrecan in rat chondrosarcoma cells treated with interleukin-1.

Authors:  J D Sandy; V Thompson; K Doege; C Verscharen
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

9.  The retinoic acid binding protein CRABP2 is increased in murine models of degenerative joint disease.

Authors:  Ian D Welch; Matthew F Cowan; Frank Beier; Tully M Underhill
Journal:  Arthritis Res Ther       Date:  2009-01-28       Impact factor: 5.156

Review 10.  Anti-ADAMTS5 monoclonal antibodies: implications for aggrecanase inhibition in osteoarthritis.

Authors:  Suneel S Apte
Journal:  Biochem J       Date:  2016-01-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.